PURPOSE: This study aimed to evaluate the efficacy and safety of the treatment with (90)Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL). EXPERIMENTAL DESIGN: From December 2006 to October 2008, 55 high-risk elderly (age > or =60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by (90)Y-ibritumomab tiuxetan 6 to 10 weeks later. RESULTS: Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80%, including 73% complete remissions and 7% partial remissions. Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after (90)Y-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85%, with a 2-year overall survival of 86%. (90)Y-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients. CONCLUSION: This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by (90)Y-ibritumomab tiuxetan in high-risk elderly DLBCL patients. (c) 2010 AACR.
PURPOSE: This study aimed to evaluate the efficacy and safety of the treatment with (90)Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL). EXPERIMENTAL DESIGN: From December 2006 to October 2008, 55 high-risk elderly (age > or =60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by (90)Y-ibritumomab tiuxetan 6 to 10 weeks later. RESULTS: Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80%, including 73% complete remissions and 7% partial remissions. Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after (90)Y-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85%, with a 2-year overall survival of 86%. (90)Y-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients. CONCLUSION: This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by (90)Y-ibritumomab tiuxetan in high-risk elderly DLBCL patients. (c) 2010 AACR.
Authors: Jonathan W Friedberg; Joseph M Unger; W Richard Burack; Ajay K Gopal; Robert N Raju; Auayporn P Nademanee; Mark S Kaminski; Hongli Li; Oliver W Press; Thomas P Miller; Richard I Fisher Journal: Br J Haematol Date: 2014-04-18 Impact factor: 6.998
Authors: Karin Hohloch; H K Lankeit; P L Zinzani; C W Scholz; M Lorsbach; C Windemuth-Kieselbach; L Trümper Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-11 Impact factor: 9.236
Authors: Mitchell R Smith; Hailun Li; Leo Gordon; Randy D Gascoyne; Elisabeth Paietta; Andres Forero-Torres; Brad S Kahl; Ranjana Advani; Fangxin Hong; Sandra J Horning Journal: J Clin Oncol Date: 2012-07-30 Impact factor: 44.544
Authors: Tapan K Nayak; Kayhan Garmestani; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel Journal: PLoS One Date: 2011-03-25 Impact factor: 3.240